IBDEI38Y ; ; 04-FEB-2020
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 04, 2020
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,51832,2)
 ;;=^5015877
 ;;^UTILITY(U,$J,358.3,51833,0)
 ;;=R30.0^^193^2513^36
 ;;^UTILITY(U,$J,358.3,51833,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,51833,1,3,0)
 ;;=3^Dysuria
 ;;^UTILITY(U,$J,358.3,51833,1,4,0)
 ;;=4^R30.0
 ;;^UTILITY(U,$J,358.3,51833,2)
 ;;=^5019322
 ;;^UTILITY(U,$J,358.3,51834,0)
 ;;=N92.1^^193^2513^39
 ;;^UTILITY(U,$J,358.3,51834,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,51834,1,3,0)
 ;;=3^Excessive/Frequent Menstruation w/ Irregular Cycle
 ;;^UTILITY(U,$J,358.3,51834,1,4,0)
 ;;=4^N92.1
 ;;^UTILITY(U,$J,358.3,51834,2)
 ;;=^5015909
 ;;^UTILITY(U,$J,358.3,51835,0)
 ;;=Z08.^^193^2513^41
 ;;^UTILITY(U,$J,358.3,51835,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,51835,1,3,0)
 ;;=3^F/U Exam After Malig Neop Treatment
 ;;^UTILITY(U,$J,358.3,51835,1,4,0)
 ;;=4^Z08.
 ;;^UTILITY(U,$J,358.3,51835,2)
 ;;=^5062667
 ;;^UTILITY(U,$J,358.3,51836,0)
 ;;=Z80.3^^193^2513^42
 ;;^UTILITY(U,$J,358.3,51836,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,51836,1,3,0)
 ;;=3^Family Hx of Breast CA
 ;;^UTILITY(U,$J,358.3,51836,1,4,0)
 ;;=4^Z80.3
 ;;^UTILITY(U,$J,358.3,51836,2)
 ;;=^5063347
 ;;^UTILITY(U,$J,358.3,51837,0)
 ;;=Z80.49^^193^2513^43
 ;;^UTILITY(U,$J,358.3,51837,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,51837,1,3,0)
 ;;=3^Family Hx of Genital Organ CA
 ;;^UTILITY(U,$J,358.3,51837,1,4,0)
 ;;=4^Z80.49
 ;;^UTILITY(U,$J,358.3,51837,2)
 ;;=^5063351
 ;;^UTILITY(U,$J,358.3,51838,0)
 ;;=Z80.41^^193^2513^44
 ;;^UTILITY(U,$J,358.3,51838,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,51838,1,3,0)
 ;;=3^Family Hx of Ovarian CA
 ;;^UTILITY(U,$J,358.3,51838,1,4,0)
 ;;=4^Z80.41
 ;;^UTILITY(U,$J,358.3,51838,2)
 ;;=^5063348
 ;;^UTILITY(U,$J,358.3,51839,0)
 ;;=N73.9^^193^2513^47
 ;;^UTILITY(U,$J,358.3,51839,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,51839,1,3,0)
 ;;=3^Female Pelvic Inflammatory Disease,Unspec
 ;;^UTILITY(U,$J,358.3,51839,1,4,0)
 ;;=4^N73.9
 ;;^UTILITY(U,$J,358.3,51839,2)
 ;;=^5015820
 ;;^UTILITY(U,$J,358.3,51840,0)
 ;;=N60.32^^193^2513^48
 ;;^UTILITY(U,$J,358.3,51840,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,51840,1,3,0)
 ;;=3^Fibrosclerosis,Left Breast
 ;;^UTILITY(U,$J,358.3,51840,1,4,0)
 ;;=4^N60.32
 ;;^UTILITY(U,$J,358.3,51840,2)
 ;;=^5015780
 ;;^UTILITY(U,$J,358.3,51841,0)
 ;;=N60.31^^193^2513^49
 ;;^UTILITY(U,$J,358.3,51841,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,51841,1,3,0)
 ;;=3^Fibrosclerosis,Right Breast
 ;;^UTILITY(U,$J,358.3,51841,1,4,0)
 ;;=4^N60.31
 ;;^UTILITY(U,$J,358.3,51841,2)
 ;;=^5015779
 ;;^UTILITY(U,$J,358.3,51842,0)
 ;;=Z01.411^^193^2513^50
 ;;^UTILITY(U,$J,358.3,51842,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,51842,1,3,0)
 ;;=3^GYN Exam w/ Abnormal Findings
 ;;^UTILITY(U,$J,358.3,51842,1,4,0)
 ;;=4^Z01.411
 ;;^UTILITY(U,$J,358.3,51842,2)
 ;;=^5062622
 ;;^UTILITY(U,$J,358.3,51843,0)
 ;;=Z01.419^^193^2513^1
 ;;^UTILITY(U,$J,358.3,51843,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,51843,1,3,0)
 ;;=3
 ;;^UTILITY(U,$J,358.3,51843,1,4,0)
 ;;=4^Z01.419
 ;;^UTILITY(U,$J,358.3,51843,2)
 ;;=^5062623
 ;;^UTILITY(U,$J,358.3,51844,0)
 ;;=Z01.419^^193^2513^51
 ;;^UTILITY(U,$J,358.3,51844,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,51844,1,3,0)
 ;;=3^GYN Exam w/ Normal Findings
 ;;^UTILITY(U,$J,358.3,51844,1,4,0)
 ;;=4^Z01.419
 ;;^UTILITY(U,$J,358.3,51844,2)
 ;;=^5062623
 ;;^UTILITY(U,$J,358.3,51845,0)
 ;;=R87.613^^193^2513^53
 ;;^UTILITY(U,$J,358.3,51845,1,0)
 ;;=^358.31IA^4^2
